With molecular sequencing as a gold standard, the Vitek MS, Bruker Biotyper MS, and Vitek-2 Compact systems correctly identified 92.7%, 97.0%, and 15.2% of 164 Candida guillermondii isolates, respectively, and none of 8 C. fermentati isolates. All of the isolates showed high susceptibility to echinocandins, but some C. guilliermondii isolates showed low azole susceptibility. . 2016.
I nvasive candidiasis (IC) is a public health threat worldwide and is considered a major cause of infection-related morbidity and mortality (1, 2) . The incidence of candidemia due to Candida guilliermondii is low, ranging from 1% to 3%, depending on the geographic region (3, 4) . However, the few available reports on C. guilliermondii infections indicate that these organisms are associated with poor clinical outcomes, which warrants further investigation (5) (6) (7) (8) (9) .
C. guilliermondii complex is a genetically heterogeneous group of phenotypically indistinguishable yeast species, including C. guilliermondii, C. fermentati, C. carpophila, and C. xestobii. Accurate and timely identification of C. guilliermondii complex isolates to the species level, including the associated antifungal susceptibility profiles, is essential for guiding clinical decisions (8) . However, there is limited information on the performance of phenotypic methods like the Vitek-2 Compact (bioMérieux, France), and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems in the identification of species within the C. guilliermondii complex in China.
C. guilliermondii complex isolates (n ϭ 172) collected from 40 hospitals in 18 provinces of China, under the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) program (2010 to 2014), were studied. We evaluated the performance of the Vitek-2 Compact (bioMérieux, France) and two MALDI-TOF MS systems, including the Vitek MS system (IVD Knowledgebase version 2.0; bioMérieux) and the Bruker Autoflex Speed TOF/TOF MS system (with Biotyper version 3.1 software; Bruker Daltonics, USA) in the identification of C. guilliermondii complex isolates. Sequencing of the ribosomal DNA (rDNA) internal transcribed spacer (ITS) region was used as the gold standard (10) .
In vitro susceptibilities of the isolates to nine antifungal drugs were determined by the Sensititre YeastOne YO10 (Thermo Scientific, USA) system as per the manufacturer's instructions. MIC values were interpreted according to the CLSI document for echinocandins (11) and epidemiological cutoff values (ECVs) for the other agents (12) . This study was approved by the relevant Human Research Ethics Committee (S-263).
Isolates were derived from 172 patients (117 males and 55 females), with an average age of 54 Ϯ 23.1 years. Detailed information on the origin of the isolates (location and specimen type) is available in Table 1 . The majority of the isolates were from surgical department (36.6%) and intensive care unit (ICU) (32.6%); pa-tients admitted in these departments are more likely to have serious underlying disease or cancer or to be immunocompromised, which may be risk factors for infections (8, 13) . Overall, C. guilliermondii complex isolates represented 1.7% (164/9,673) of all the yeast isolates for the 5-year study period and specifically accounted for 2.6% (106/4,122) of all yeasts from blood cultures.
Among the 172 C. guilliermondii complex isolates, 164 (95.3%) isolates were confirmed as C. guilliermondii and 8 as C. fermentati by ITS gene sequencing. Identification results obtained by the Vitek-2 Compact and the two MALDI-TOF MS systems are shown in Table 2 . By using an acceptable confidence value of 99.9% for the Vitek MS system and an identification score of Table 3 . All three echinocandins exhibited good antifungal activity against the 164 C. guilliermondii isolates (97% to 99.4%). For azoles, itraconazole showed the highest susceptibility rate (96.9%), followed by posaconazole (95.7%), voriconazole (90.2%), and fluconazole (89.0%). Sixteen (9.7%) isolates were cross-resistant to azoles, including five (3.0%) that were of the non-wild-type (WT) phenotype to all four azoles tested. Moreover, 93.9% and 100% of the isolates were assigned to be WT by ECVs to 5-flucytosine and amphotericin B, respectively. The eight C. fermentati isolates were all susceptible to the three echinocandins by breakpoints (BPs) and belonged to the WT for the other agents by ECVs.
In the present study, 2.6% of all candidemia cases were caused by C. guilliermondii, which is similar to findings elsewhere (1 to 3%) (3, 4) . In addition, a rise in the rate of isolation of C. guilliermondii was observed in the last 3 years (2012 to 2014) of the CHIF-NET program, which ultimately reached 3.7% in 2014. This sharp rise in the isolation rate of this organism, especially in bloodstream infections, is a cause for concern which warrants further surveillance. Previous studies indicated that C. fermentati strains constitute about 9% of all species in the C. guilliermondii complex (14, 15) , which disagrees with our study in which only 4.7% (8/172) were detected.
The Vitek-2 Compact system performed poorly in the identification of the 164 C. guilliermondii isolates, with only 15.2% of isolates correctly identified to the species level, which is similar to the results of previous studies (16, 17) . Furthermore, there was also a low discrimination rate of 74.4% (122 isolates) between C. famata and C. guilliermondii, and 10.4% (17 isolates) was misidentified as C. famata. The misidentification of C. guilliermondii may result in inappropriate treatment, especially given the high antifungal resistance associated with this species (18) . Although there are differences between the two MALDI-TOF MS systems that affect spectra quality and hence identification scores and accuracy, both the Vitek MS and Bruker Biotyper MS systems exhibited high accuracy rates for identification of C. guilliermondii isolates, which is in agreement with our previous studies (19) . The two MALDI-TOF systems may be effective tools for rapid routine identification of C. guilliermondii in the clinical microbiology laboratory, especially when labor and cost factors are considered.
In the present study, fluconazole showed the lowest activity against C. guilliermondii compared with that of the other azoles, with a WT rate of 89.0%, which is higher than the data reported from the global ARTEMIS DISK Antifungal Surveillance Program (75%) (3). Some of our isolates were a little less susceptible to the nine antifungal agents than in another study in Taiwan (96% to 100%) (13) . Although cross-resistance to azoles has been reported sporadically in the literature (7-9), 9.7% of the isolates in the present study showed cross-resistance to azoles, which is an important consideration for antifungal therapy. Although the majority of the isolates were susceptible to echinocandins, the MICs for C. guilliermondii have been observed to be much higher than those for other common Candida species (14, 15) .
The study is limited by the lack of representation of all species within the C. guilliermondii complex and the small number of C. fermentati isolates analyzed. Furthermore, not all C. guilliermondii complex species are covered in the Vitek MS and Bruker databases, which can affect identification accuracy. Performance may be improved by adding MSPs into the current databases.
